About Revance Therapeutics
Revance Therapeutics is a Healthcare company based in Newark (United States) founded in 2002, and was acquired by Crown Laboratories in February 2025. Neurotoxin products for aesthetic and therapeutic skin treatments are developed. Revance Therapeutics has raised $154.56 million across 5 funding rounds from investors including Crown Laboratories, SVB Securities and Medicis Pharmaceutical. The company has 597 employees. Revance Therapeutics has completed 1 acquisition, including HintMD. Its chief executive, as recorded, is Mark Foley. Its website revance.com draws about 18 thousand monthly visits. Revance Therapeutics offers products and services including DAXXIFY, Hyaluronic Acid Filler, and Microneedling Brand. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its legal entity is Revance Therapeutics, Inc. Its competitors include Castle Creek Pharma, Dermavant and Sol-Gel Technologies; 3 of its 3 listed competitors have raised funding.
Company details
Revance Therapeutics was founded in 2002 and is headquartered in Newark, United States. Operations focus on the aesthetic medicine sector, where innovative neurotoxin products for skin treatments are developed. A proprietary platform technology is used to facilitate delivery of large macromolecules across the skin. The pipeline includes RT001 for lateral canthal lines and RT002 for glabellar lines, with applications extended to therapies for Hyperhidrosis and Cervical Dystonia.
- Headquarters Newark, United States
- Employees 597
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website revance.com
- Social LinkedIn X Facebook Instagram
- Acquired by Crown Laboratories (Feb 2025)
- Legal Name Revance Therapeutics, Inc.
- Annual Revenue$234.04 M (USD)77as on Dec 31, 2023
- Net Profit-$323.99 M (USD)9as on Dec 31, 2023
- EBITDA-$310.65 M (USD)1as on Dec 31, 2023
- Total Equity Funding$154.56M (USD)
in 5 rounds
- Latest Funding Round$10M (USD), Series E
Oct 2013
- InvestorsCrown Laboratories
& 12 more
- Employee Count597
- Investments & Acquisitions
- Acquired byCrown Laboratories
(Feb 2025)
Products & Services of Revance Therapeutics
Revance Therapeutics offers a comprehensive portfolio of products and services, including DAXXIFY, Hyaluronic Acid Filler, and Microneedling Brand.
Acetylcholine release inhibitor for treating glabellar lines in adults.
Product for aesthetic enhancements and skincare applications.
Device for skin rejuvenation and therapeutic applications.
Funding Insights of Revance Therapeutics
Revance Therapeutics has successfully raised a total of $154.56M across 5 strategic funding rounds. The most recent funding activity was a Series E round of $10 million completed in October 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $154.56M
- Total Rounds 5
- Last Round Series E — $10M
- First Round $43.2M
(Dec 2007)
- Investors Count 12
All 5 funding rounds of Revance Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2013 | $10M | Series E | – | – | – |
| Feb 2013 | $33M | Series E | – | Delphi Ventures, EW Healthcare Partners | – |
| Jan 2013 | $63.36M | Series D | – | EW Healthcare Partners, NovaQuest Capital Management | |
| Feb 2011 | $5M | Series C | – | – | – |
| Dec 2007 | $43.2M | Series C | – | Medicis Pharmaceutical |
13 investors in total: 13 institutional.
Investors in Revance Therapeutics
Revance Therapeutics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Crown Laboratories, SVB Securities and Medicis Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in life sciences firms across all stages. | delphiventures.com | Menlo Park, United States | ||
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | ewhealthcare.com | New York, United States | ||
Investments are made in US life sciences and energy companies. | technologypartners.com | Palo Alto, United States | ||
Early-stage US companies are invested in by Shepherd Ventures. | shepherdventures.com | San Diego, United States | ||
Healthcare sector investments are managed through private equity strategies. | pa-investors.com | Palo Alto, United States | ||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Wealth is managed for the Clark family by Clark Enterprises. | clarkenterprises.com | Bethesda, United States | ||
PE firm focused on life science and healthcare companies | novaquest.com | Raleigh, United States | ||
Healthcare advancements are driven by IQVIA through connected intelligence. | quintiles.com | United States | ||
| essexcapitalcorp.com |
Investor details for Revance Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Revance Therapeutics
15 people are tracked at Revance Therapeutics (7 in leadership, 7 in board & advisors, 1 in team); the tracked headcount is 597.
| Name | Role | Group |
|---|---|---|
John D Rogers | Vice President | Leadership |
Mark Foley | CEO | Leadership |
David A. Hollander | Chief Medical Officer | Leadership |
Amie Krause | Chief People Officer | Leadership |
Nick Crowe | COO | Leadership |
Scott Leffler | CFO | Leadership |
Kira Schwartz | Chief Legal Officer | Leadership |
Julian S. Gangolli | Board Member | Board & advisors |
Angus C. Russell | Chairman of the Board | Board & advisors |
Chris Nolet | Chair, Audit Committee | Board & advisors |
Olivia C. Ware | Board Member | Board & advisors |
Vlad Coric | Board Member | Board & advisors |
Jill Beraud | Board Member | Board & advisors |
Carey O’Connor Kolaja | Board Member | Board & advisors |
Dwight Moxie | SVP, General Counsel & Corporate Secretary | Team |
Complete people profiles for Revance Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Revance Therapeutics
Revance Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include HintMD.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Users are connected to aesthetic physicians for customized treatment plans. | hintmd.com | Pleasanton, United States | 2014 | May 2020 | •••• |
Complete acquisition details for Revance Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Revance Therapeutics
6 dated milestones of Revance Therapeutics across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Revance Therapeutics is founded.
- Funding First funding round of $43.2M.
- Funding Latest funding round, Series E, of $10.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires HintMD.
- Exit Acquired by Crown Laboratories.
Competitors of Revance Therapeutics
Revance Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Castle Creek Pharma, Dermavant and Sol-Gel Technologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| castlecreekpharma.com | 2015 | Basking Ridge, United States | $663.15M | 72 | Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | |
| dermavant.com | 2016 | Phoenix, United States | $160M | Small molecule therapeutics for inflammatory skin diseases are developed. | ||
| sol-gel.com | 1998 | United States | $9M | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. |
Detailed competitors of Revance Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Revance Therapeutics
The website of Revance Therapeutics (revance.com) receives about 17.8K visits a month and ranks #1,318,141 among all websites worldwide, #1,701 in Biotechnology and Pharmaceuticals.
- Monthly visits17.8K
▼ 10.4% vs previous month
- Unique visitors9.1K
per month
- Global rank#1,318,141
among all websites
- Category rank#1,701
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit2.0
- Average visit32 sec
- DevicesDesktop 35% · Mobile 65%
Websites whose visitors overlap most with Revance Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| esperion.com | 100% | 16.4K | #1,899,294 | View details | |
daxxify.com | daxxify.com | 100% | #691,722 | – | |
| pearltherapeutics.com | 94% | View details | |||
| amicusrx.com | 86% | 20.4K | #1,355,769 | View details | |
| karyopharm.com | 86% | 11.8K | #3,094,808 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Revance Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as Revance Therapeutics (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608.25 M | 197 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Revance Therapeutics
Complete news archive for Revance Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Revance Therapeutics
Revance Therapeutics was founded in 2002 and raised its 1st funding round 5 years after it was founded.
Revance Therapeutics is headquartered in Newark, United States. It is registered at Newark, New Jersey, United States.
Mark Foley is the CEO of Revance Therapeutics, as recorded in our data.
Revance Therapeutics is a funded company, having raised a total of $154.56M across 5 funding rounds to date. The company's 1st funding round was a Series C of $43.2M, raised on Dec 2007.
Revance Therapeutics has 597 employees.
Annual revenue of Revance Therapeutics is $234.04M as on Dec 31, 2023.
Revance Therapeutics was founded in 2002 and is headquartered in Newark, United States. Operations focus on the aesthetic medicine sector, where innovative neurotoxin products for skin treatments are developed. A proprietary platform technology is used to facilitate delivery of large macromolecules across the skin. The pipeline includes RT001 for lateral canthal lines and RT002 for glabellar lines, with applications extended to therapies for Hyperhidrosis and Cervical Dystonia.
Revance Therapeutics's top competitors include Dermavant, Sol-Gel Technologies and Castle Creek Pharma.
Revance Therapeutics offers DAXXIFY, Hyaluronic Acid Filler, and Microneedling Brand.
Revance Therapeutics has made 1 acquisition, including HintMD.
Revance Therapeutics has 13 investors. Key investors include Crown Laboratories, SVB Securities, Medicis Pharmaceutical, Delphi Ventures, and EW Healthcare Partners.
Revance Therapeutics operates through Revance Therapeutics, Inc..